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002 The Journal of Thoracic and Cardbjectives: Radiofrequency ablation of lung tumors is an emerging technique with
romising results. To achieve more information on its effects on pulmonary paren-
hyma and primary tumors, and to assess its efficacy in determining complete
ecrosis of the lesion, we led a pilot study consisting of thermal ablation followed
y surgical resection.
ethods: Ten patients with early stage non–small cell lung cancer were enrolled in
he study. In 5 patients radiofrequency ablation was achieved through thoracotomy
ust before the surgical resection. In another 5 patients radiofrequency ablation was
erformed percutaneously, under computed tomography guidance, and the surgical
esection was performed after 15 days.
esults: Nine of the 10 patients enrolled in the study were available for analysis.
here were 8 men and 1 woman with a mean age of 65.5 years. In all cases histologic
iagnosis was available before radiofrequency ablation; adenocarcinoma was identified
n 5 patients, and squamous cell carcinoma was identified in 4 patients. Microscopic
xamination showed complete necrosis of the tumor in 6 of 9 cases. No anatomopatho-
ogic alterations were seen in surrounding distant parenchyma.
onclusions: Our study confirms the safety of radiofrequency ablation, particularly
nderlining the possibility of performing a thermal lesion in the lung in a controlled
anner. It also assesses that radiofrequency ablation may be effective in the local
ontrol of primary lung cancer. However, surgery still represents the mainstay of
reatment of non–small cell lung cancer, and radiofrequency ablation must be reserved
or high-risk patients.
 
he results of the present modalities of treatment of non–small cell lung
cancer (NSCLC) are poor in all but stage I disease.1 Surgery still represents
the treatment with the greatest chance of cure in case of localized disease
stages I, II, and IIIa); nevertheless, surgical treatment is not always feasible because
f medical contraindications or refusal by the patient. In this case, chemotherapy
nd radiotherapy, alone or in combination, give a modest therapeutic contribution,
rimarily the palliative sort.2
In this scenario it is understandable that minimally invasive treatments often
eceive great interest, as is now happening for radiofrequency thermal ablation
RFA). This method has been successfully used for the treatment of many solid
umors.3-7 Thin, metallic probes, similar to aspiration biopsy needles, are percuta-
eously inserted into the lesion using computed tomography (CT) scanning or
ltrasound guidance. Radiofrequency energy is then applied to achieve a tempera-
ure greater than 60°C (in most cases 90°C). Thus, coagulative necrosis of the tumor
s induced in a controlled manner.
More recently this technique has been applied to pulmonary tumors, showing
romising preliminary results.8-11 All of the recently reported clinical trials analyzed
iovascular Surgery ● May 2006
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G
TShe results of the procedure from a radiologic point of view.
owever, little is still understood about the biologic effects
f RFA on the human lung and its tumors.
After an initial experience using an animal model,12 we
ransferred this technique to human lung tumors. The object
f this articles concerns the results of 2 “ablate and resect”
rotocols, which provided for radiofrequency ablation of
he tumor followed by surgical resection. To our knowledge
his is the largest single institutional series.
aterials and Methods
his study was conducted with the approval of the local ethical
ommittee for human research care.
adiofrequency Generator and Devices
e used a generator able to provide monopolar radiofrequency
nergy to perform coagulation and ablation of soft tissue (Model
500, RITA Medical System, Mountain View, Calif). This is an
utomatic apparatus with a maximum power output of 150 W
operating at 460 Hz). It has multiple temperature displays as well
s impedance and power monitoring. The energy was transferred
nto the tissue by means of a disposable array (StarBurst XL, RITA
edical System). It consists of a 15-gauge needle with 9 deploy-
ble electrodes that open in a flower-like manner up to 5 cm
Figure 1). Five electrodes are equipped with a thermocouple to
ontinuously measure the temperature inside the tissue. Two dis-
ersive electrode pads were applied to each shaved leg to ground
he current and to reduce risks of skin heat injuries. Once the
ystem was powered up, the physician set the parameters of the
blation: the mode of operation (we used “average temperature
ode,” in which delivered power was automatically regulated to
aintain the target temperature set); target temperature; ablation
ime at target temperature; and maximum power delivery level,
hich can be modified at any time during the procedure.
ntry Criteria
atients were required to meet the following specific criteria for
nrollment, in addition to those standard to tolerate major pulmo-
ary resection: at least 18 years of age; preoperative histologic
roof of the tumor; clinical stage I and II NSCLC (assessed by CT
can); maximum diameter of the tumor less than or equal to 3.5
m, and farther than 1 cm from major blood vessels or airways;
nd signed informed consent.
Exclusion criteria included patients aged more than 75 years,
ith pleural effusion, or who required a resection greater than a
Abbreviations and Acronyms
CT  computed tomography
NADH  reduced nicotinamide adenine dinucleotide
NSCLC non–small cell lung cancer
RFA  radiofrequency ablationobectomy. a
The Journal of Thoracicadiofrequency Ablation Procedure and Surgical
esection
n the first protocol, RFA was performed during open surgery.
ith the patient under general anesthesia and selective intubation,
thoracotomy was performed to allow surgical resection. The
obar hilum was isolated to allow quick surgical resection in case
f complications, but blood supply and ventilation were preserved
o reproduce better physiologic conditions. The needle was in-
erted into the tumor by digital palpation guidance, and the elec-
rodes were deployed with the lung deflated to permit better
acility for correctly placement of the device into the lesion. The
enerator was powered up and radiofrequency ablation was per-
ormed with the lung ventilated again; standard vital signs of the
atients were recorded. At the end of the procedure, the electrodes
ere retracted and the needle was withdrawn slowly with a rotatory
otion. A lobectomy with mediastinal lymph node dissection was
hen completed as planned. RFA and surgical resection were always
erformed by the same surgeons (MCA and AM, respectively).
In the second protocol, the patients underwent percutaneous
FA by CT guidance, under local anesthesia and conscious seda-
ion. Surgical resection was delayed 15 days after the thermal
blation and a lobectomy, with mediastinal lymph node dissection,
erformed in all cases. In these patients, RFA was always per-
ormed by a surgeon (MCA) and radiologist (RC), and the surgical
esection was performed by the same surgeon (AM).
In all cases the target temperature was 90°C, which was main-
ained for 15 to 27 minutes according to the size of the tumor and,
onsequently, the deployment of the electrodes. When technically
ossible, we always pursued the objective of encompassing the
eoplastic lesion with a thermal one of at least 1 cm larger.
At the end of the surgical resection, all specimens were pro-
essed for pathologic evaluation.
natomopathologic Study
he specimens were sectioned across the maximum diameter, and
acroscopic findings were recorded. They were preserved in a
ormalin solution and immediately transferred to our pathology
nit for microscopic analysis, which was performed on average 36
ours after resection by 2 highly qualified pathologists with con-
olidated experience on lung cancer (GF and PF). The protocol
rovides that the specimen is fixed in 40% phosphate-buffered for-
alin and that the thermal lesion (including the tumor) is divided into
to 4 blocks (according to the size of the lesion). Each block is cut at
ntervals of 30 m (levels). For each level, 2 sections (5 m) are
btained by microtome, all of which are routinely stained for histo-
ogic examination using alternately hematoxylin-eosin staining. The
ections were examined by both pathologists using a light microscope
ith low (4-10) and high (40) zoom lenses. Multiple samplings
ere made around the treated area: Two samples were taken 1 cm
istant from the treated area, 2 samples were taken 2 cm distant
rom the treated area, and 2 samples were taken in the surrounding
arenchyma, far from the thermal lesion.
esults
en patients were enrolled in this study, but in 1 case the
atient refused surgical resection after percutaneous RFA,
nd therefore was not available for analysis. Of the remain-
and Cardiovascular Surgery ● Volume 131, Number 5 1003
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TSng 9 patients, 8 were male and 1 was female with a mean
ge of 65.5 years (range 55-70 years). In all cases histologic
iagnosis was available before RFA; we identified adeno-
arcinoma in 5 patients and squamous cell carcinoma in 4
atients. All lesions were peripheral with a mean size of 2.8
m (range 1.5-3.5). Postoperative pathologic staging was
tage I in 6 cases and stage II in 3 cases. Overall time for the
ntire ablation was 24 minutes on average (range 18-33
inutes). This includes the time of RFA at target tempera-
ure (19 minutes on average) and the time to reach the target
emperature (5 minutes on average), at start and every time
t was lost after the serial expansion of the electrodes.
No complications related to RFA were observed during,
fter, and at the moment of surgical resection in the delayed
roup. Postoperative hospital stay was uneventful.
In all cases the thermal lesion encompassed the tumor.
n macroscopic examination it appeared as rounded blood-
ess necrotic tissue with a diameter of 4.1 cm on average
range 2.9-5.3 cm). A central cavitation was surrounded by
hite coagulated tissue, partially carbonized in some cases.
n patients who underwent immediate surgical resection, a
eripheral reddish rim was well demarcated from both the
entral coagulated tissue and surrounding normal-appearing
arenchyma. Lesions observed in patients who underwent004 The Journal of Thoracic and Cardiovascular Surgery ● Maercutaneous RFA and delayed resection were better de-
arcated, and a thin rim of light fibrous scar tissue was
bserved at the periphery of the lesion, replacing the red
amaged area (Figure 2). Microscopic examination showed
he presence of coagulation necrosis. In particular, the cy-
oplasm lost its structural detail (eg, granularity and striations)
nd resembled coagulated material, thus the term “coagulative
ecrosis.” The cytoplasm was more eosinophilic (pinkish red)
ecause of loss of hematoxylin-binding ribosomes and in-
reased affinity for eosin. The nucleus shrinks irregularly and
tains more deeply (pyknosis), breaks up into fragments (kary-
rrhexis), and finally fails to stain with hematoxylin (karyoly-
is). This is caused by the action of released lysosomal en-
ymes, that is, proteases, exonucleases, and phosphatases. No
iable tissue was visible within the necrotic area, except at
ts extreme periphery where some nests of viable cells
ersisted, particularly along the bigger vessels. Early in-
ammation cells, edema, and damaged alveoli were seen
ithin 1 cm peripherally of the necrotic nodule. However,
o injury was noted within this peripheral area in blood
essels and bronchi, except for a dilatation of smaller ves-
els. No anatomopathologic alterations were seen in the
urrounding distant parenchyma (2 cm from the periphery
f the necrotic area). The only difference in the specimens
Figure 1. CT images during and just after
percutaneous radiofrequency ablation of an
NSCLC. It is to observe the ground-glass den-
sity area of the thermal lesion encompassing
the neoplastic one.
Figure 2. Macroscopic and microscopic re-
ports of an NSCLC resected 15 days after
percutaneous CT-guided RFA showing com-
plete coagulation necrosis.y 2006
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G
TSbtained 15 days after RFA was the presence of granulation
issue surrounding the necrotic area, with the inflammatory
ells that were cleaning up damaged tissue and leading scar
issue synthesis. Still, no damage was observed in the pa-
enchyma surrounding the thermal lesion.
Complete necrosis of the tumor was recorded in 6 of 9
ases (Figure 2). In these patients the mean size of the
eoplastic lesion was 2.3 cm. Clusters of viable but injured
umor cells were observed in 3 patients, principally at the
eriphery of the lesion (2 patients who underwent immedi-
te resection and 1 patient who underwent delayed resec-
ion). The clusters represented no more than 10% of the
reated area and, in many cases, appeared completely sur-
ounded by necrotic tissue, probably without blood supply.
ven if the thermal lesion completely encompassed the
umor, its margins from the neoplastic lesion appeared
horter (5 mm in all 3 cases) than in the patients with
omplete ablation (8 mm on average). Moreover, the mean
ize of the lesions in case of incomplete ablation was 3.1
m, larger than that of those completely ablated but without
tatistical significance. There were no other significant dif-
erences between the group with complete necrosis and the
roup with incomplete ablation.
The patient who refused surgical resection after percutane-
us RFA is still alive and locally disease-free at a follow-up
eriod of 33 months. A second tumor recently developed in his
ontralateral lung, which was still treated by RFA.
iscussion
ince thermal ablation of a pulmonary tumor using radio-
requency was first achieved by Lilly and colleagues in
983,13 much has been learned. Currently, many articles
eport promising clinical results in performing percutaneous
hermal ablation of primary or secondary lung tumors.8-11
otwithstanding that in recent years a great amount of data
n the clinical and radiologic response of RFA on lung
umors have accumulated, its biologic effects remain poorly
nderstood.
The first “ablate and resect” model of pulmonary neo-
lasms was described by Goldberg and colleagues in 199614
n an animal model with a pulmonary tumor induced by
eans of injection of a suspension of sarcomatose cells
X2. Seven rabbits, each with a tumor 6 to 12 mm in
iameter, were treated for 6 minutes at 90°C. The anato-
opathologic examination, executed at several intervals of
ime after treatment, showed the presence of a necrotic area
ith absence of neoplastic cells in 95% of the cases.
Steinke and colleagues,15 in 2002, published the first article
escribing an “ablate and resect” protocol in a single patient.
hey performed CT-guided radiofrequency ablation of a pul-
onary metastasis followed by surgical resection. Histologic
orkup, 3 weeks postablation, showed complete devitalization
f the metastasis. An abstract by Scott and colleagues,16 pre- d
The Journal of Thoracicented at the 10th World Conference on Lung Cancer in 2003,
eported a 100% of necrosis in 4 of 5 patients (80%). Our
xperience confirms and strengthens their findings. As ex-
ected, as the number of cases increased, more failures of the
rocedure were observed. In 3 of 9 cases, clusters of viable
umor cells were observed. They represented no more than
0% of the treated area and appeared injured and completely
urrounded by necrotic tissue, probably without blood supply.
he same authors recently published an extension of the
tudy.17 They reported 100% necrosis in 3 of 8 patients
37.5%) and more than 80% tumor necrosis in 4 of 5 of the
emaining patients. They used supravital staining (reduced
icotinamide adenine dinucleotide [NADH]), maintaining that
t “was the only histopathologic method capable of differenti-
ting viable from ablated tissue,” yet without supporting the
tatement with references. We also discussed the opportunity
o use this method with our pathologist and decided not to use
ADH staining. The method is very delicate and requires a
rocedure that we were not able to reproduce correctly, pri-
arily because our thoracic surgery unit and pathology unit are
ocated in 2 different hospitals. Nguyen and colleagues17 ex-
luded a patient because of an incorrectly performed supravital
tain. Moreover, even if NADH staining could supply some
ore details about cell viability in tumor cells that are not
learly dead, necrosis is always well assessed by standard
ematoxylin-eosin staining.18 Their results, worse than those
f our experience despite NADH staining, could be explained
ith the differences in the 2 pilot studies. In fact, even if the
ean size of the lesions was similar (2.2 vs 2.8 cm), they used
ifferent technology and RFA protocols. Their device to bring
adiofrequency energy into the tumor had a single electrode of
or 3.5 cm; our needle had 9 electrodes that were deployable
n a flower-like manner for 5 cm, which allows better encom-
assment of the tumor. Moreover, the mean time of RFA was
lmost double in our series. Both of these aspects may justify
he better results in our experience. Our “ablate and resect”
rotocol reports an overall success rate of RFA in local erad-
cation of NSCLC of approximately 67%, which is similar to
hose recently reported in clinical trials.10,11 When wedge
esection is used, it is important to obtain wide margins
etween the tumor and the staple line. It is not surprising
hat in the cases in which the tumor was not completely
blated, the margins of ablation were smaller.
Another aspect underlined and strengthened in this study
as the absence of damage in peripheral lung parenchyma
ore than 1 cm distant from the thermal lesion. The thermal
esion, in fact, seems to limit itself in the lung, probably
ecause of ventilation and blood supply of normal paren-
hyma. We12 and Goldberg and colleagues19 have reported
uch encouraging phenomenon in previous articles on animal
odels. In both experiences, the most important aspect was
recisely this auto-limitation of the thermal injury itself, which
id not affect the peripheral parenchyma. Furthermore, Gold-
and Cardiovascular Surgery ● Volume 131, Number 5 1005
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TSerg and colleagues observed that the dimensions of the lesion
nduced in pulmonary parenchyma were lower than those
nduced in other solid organs like the liver. They related these
acts to the high impedance of the inflated lung that reduces
ropagation of radiofrequency waves. This behavior could
rove to be useful in RFA of solid pulmonary neoplasms. In
act, the energy would be adequately propagated in the solid
issue, obtaining coagulation and necrosis, while the surround-
ng healthy parenchyma would be protected from air inflation
ith a kind of physiologic auto-delimitation of the thermal
amage. Such a supposition has been confirmed in this study.
he thermal lesions were on average 1.3 cm larger than the
eoplastic ones and were well-demarcated from the surround-
ng parenchyma, which showed no macroscopic or micro-
copic alterations 1 cm or more distant from the periphery of
he necrotic area.
onclusion
he feasibility and safety of RFA of lung tumors have been
ecently assessed in several articles in the literature, whereas its
fficacy still remains to be determined. This study confirmed
he safety of the procedure, particularly underlining the possi-
ility of performing a thermal lesion in the lung parenchyma in
controlled manner, but, above all, the capability of RFA to
roduce complete necrosis of a lung tumor, as it was histolog-
cally proven in 67% of patients in our series. A limitation of
his pilot study is the number of the enrolled patients. Even if,
o our knowledge, this is the largest reported series, it is
equired that other similar studies confirm our results. Cer-
ainly it is necessary to underline the purpose of RFA, which is
nly the local treatment of the tumor, with all its limits. In fact,
hen wedge resection is compared with lobectomy, when we
reat a lung tumor with RFA instead of surgical resection,
espite a successful procedure, a high recurrence rate is ex-
ected. Well-designed clinical trials, with long-term follow-up,
re required to confirm the preliminary results before RFA can
nter into clinical practice. However, since wedge resection
s considered a compromise operation with respect to lo-
ectomy, then RFA must be considered a compromise pro-
edure with respect to surgical resection in high-risk pa-
ients.
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